Advertising at this time would be a waste of money. I am quite sure they have many activities ongoing to 'advertise' and communicate their company updates with institutional investors and potential partners. That is the most valuable target audience right now and I am quite certain that it is happening. We don't see it but that is fine. The coiled spring you speak of will pop even more as institutions invest after the uplist. I could see new a new website as we get closer to the uplist so there is a nicer look and feel on the Nasdaq with updated content. I would highly recommend that GC if you read this board. Lol. Could also see more of a PR push around uplist and the spin off of the Diagnostic Division. That would be money well spent.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links